Quantcast

Industry news that matters to you.  Learn more

Scientists Discover Concussion Biomarker

The secret to reliably diagnosing concussions lies in the brain’s ability to process sound, according to a new study by researchers from Northwestern University’s Auditory Neuroscience Laboratory.

Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in Cerebral Spinal Fluid for Patients with Lung Cancer that has Spread to the Brain

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces a collaboration on a biopharmaceutical company clinical trial analyzing biomarkers using both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF). The trial is being conducted in patients with non-small cell lung cancer (NSCLC) whose disease has spread to the brain or membranes surrounding the brain and spinal cord, known as leptomeningeal disease.

Quanterix’s Single Molecule Array Technology Unlocks New Biomarker Fueling Advancements in Neurological Research

Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, recently announced that its Single Molecule Array technology (Simoa) was prominently featured in three recently published research papers, highlighting applications for a promising new brain biomarker never before measured in blood, referred to as neurofilament light (NFL), which was shown to be indicative of neuronal injury.

Leading Research Funders Build On Global Initiative With New Nearly $2 Million Commitment To Study Commonalities Of Neurodegenerative Diseases

Together, leading funders of research in the U.S., Canada and U.K. are advancing a global funding initiative aimed at better understanding the similarities and differences between progressive brain-deteriorating diseases, such as Alzheimer’s and Parkinson’s, with an expanded partnership and increased funding.

Smell And Eye Tests Show Potential To Detect Alzheimer’s Early

A decreased ability to identify odors might indicate the development of cognitive impairment and Alzheimer’s disease, while examinations of the eye could indicate the build-up of beta-amyloid, a protein associated with Alzheimer’s, in the brain, according to the results of four research trials reported recently at the Alzheimer’s Association International Conference® 2014 (AAIC® 2014) in Copenhagen.